Vorinostat - Unravel Biosciences
Alternative Names: RVL-001Latest Information Update: 10 Sep 2025
At a glance
- Originator Unravel Biosciences
- Class Antineoplastics; Hydroxamic acids; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Pitt-Hopkins syndrome; Rett syndrome
Most Recent Events
- 02 Sep 2025 Unravel Biosciences plans a phase I trial for Pitt Hopkins Syndrome (In children, In adolescents, In adults) in Colombia (PO, Suspension) (NCT07150026)
- 20 Feb 2025 Phase-0 trials in Pitt-Hopkins syndrome in USA (unspecified route) prior to February 2025 (Unravel Biosciences Pipeline, February 2025)
- 20 Feb 2025 Phase-0 trials in Rett syndrome in USA (unspecified route) prior to February 2025 (Unravel Biosciences Pipeline, February 2025)